Viewing nowKyungbo Clopidogrel Tablets (Clopidogrel Sulfate)
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Kyungbo Pharmaceutical Co., Ltd.

MFDS item code 201300318 · Approved 2013.01.09 · Insurance code 665001700
Improvement of symptoms of atherosclerosis and acute coronary syndrome; reduction of thrombotic risk in atrial fibrillation
This medication is used to improve atherosclerotic symptoms in adults with ischemic stroke, myocardial infarction, or peripheral arterial disease. It also helps prevent cardiovascular complications and improve atherosclerotic symptoms in patients with acute coronary syndrome or those who have undergone coronary interventional procedures or coronary artery bypass surgery. Furthermore, it reduces the risk of stroke and thromboembolism in patients with atrial fibrillation who have vascular risk factors and for whom Vitamin K antagonists are not appropriate. Overall, it helps reduce the risk of cardiovascular disease and enhance health.
1. In patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. In patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), initiate treatment on the first day with a loading dose of 300 mg of this medicine once daily, followed by a maintenance dose of 75 mg orally once daily. In these patients, 75 ~ 325 mg of aspirin should be administered concomitantly with this medicine once daily. 3. In patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. In these patients, 75 ~ 100 mg of aspirin should be administered concomitantly with this medicine once daily. ○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment: Treatment experience in patients with moderate liver disease with a bleeding diathesis is limited. This medicine may be administered with or without food.
This medication helps prevent platelet aggregation, allowing blood to flow more easily. People genetically deficient in the enzyme CYP2C19, which activates this medication, may experience reduced effectiveness, and in such cases, alternative treatments should be discussed with a physician. Additionally, concomitant use with drugs that activate the CYP2C19 enzyme may increase the active ingredient concentration of this medication, raising the risk of bleeding; thus, such combinations are not recommended. Patients with allergies to this medication or its components, those with severe bleeding, very poor liver function, nursing mothers, or individuals with specific genetic disorders such as lactose intolerance should not take this medication. Those with allergies to soybean oil, soy, or peanuts should use this medication with caution. Patients at high risk of bleeding should notify their doctor immediately if they experience any bleeding symptoms while on this medication, and if surgery is planned, it should be discontinued 5–7 days prior to the procedure. This medication may increase the risk of bleeding when taken with other antiplatelet agents, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs), so caution is advised. During treatment with this medication, gastrointestinal bleeding, intracranial bleeding, and various bleeding events may occur; hence, if any bleeding symptoms arise, immediate consultation with healthcare professionals is necessary. Rarely, side effects such as reduced blood cell counts may occur, so it is advisable to get tested if fever or signs of infection develop. While this medication does not have a significant impact on the fetus during pregnancy, there is a risk of bleeding during delivery; thus, it is recommended to discontinue use before delivery. If breastfeeding, consultation with a physician regarding whether to continue or discontinue breastfeeding is necessary due to the potential for this medication to be excreted in breast milk. The safety and efficacy of this medication in children have not yet been established, so it should be used cautiously in pediatric patients. Elderly patients may have decreased bodily functions, increasing the risk of side effects such as bleeding, so dose adjustments and monitoring of condition are necessary. In cases of overdose, bleeding may worsen, and as there is no specific antidote, immediate medical attention is required. This medication should be stored out of reach of children and not transferred to other containers.
Hemorrhage, gastrointestinal bleeding, hospital-required bleeding, purpura, contusion, hematoma, epistaxis, hematoma, hematuria, intraocular hemorrhage, intracranial hemorrhage, major bleeding, life-threatening hemorrhage, fatal hemorrhage, hemorrhagic stroke, need for blood product, need for transfusion, significant degree of functional impairment, intraocular hemorrhage with significant vision loss, minor bleeding, neutropenia, agranulocytosis, aplastic anemia, thrombocytopenia, abdominal pain, dyspepsia, diarrhea, nausea, rash, pruritus, chest pain, accidental injury, influenza-like illness, pain, fatigue, edema, hypertension, headache, dizziness, depression, upper respiratory infection, shortness of breath, rhinitis, bronchitis, cough, urinary tract infection, syncope, palpitations, asthenia, fever, hernia, heart failure, atrial fibrillation, leg cramps, sensory neuropathy, neuralgia, sensory disturbance, vertigo, constipation, vomiting, elevated liver enzymes, gout, hyperuricemia, non-protein nitrogen increased, arthritis, arthrosis, anxiety, insomnia, anemia, bloody stool, thrombocytopenia, pneumonia, sinusitis, eczema, skin ulcer, cystitis, cataract, conjunctivitis, decreased motor function, tremor, voice disorder, abnormal gait, hyperkinesia, ataxia, perception disturbance, insomnia, depression, forgetfulness, cognitive disturbance, abnormal behavior, rigidity, facial edema, purpura syndrome, hemothorax, herpes zoster, erythematous rash, maculopapular rash, urticaria, renal dysfunction, acute renal failure, gynecomastia, prostate-specific antigen elevation, anorexia, weight loss, visual disturbance, alopecia, weight gain, facial flushing, thirst, dysphagia, tongue disorders, urinary dysfunction, uremia, hypoglycemia, bradycardia, tinnitus, contact dermatitis, cholecystitis, hematemesis, spinal hematoma
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the effectiveness and safety of the medication.
Pink, round, film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowClopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Kyungbo Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Geonil Pharmaceutical Co., Ltd.
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Sama Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
(Co., Ltd.) Korea Pharma

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.